Wells Fargo downgrades NxStage Medical (NXTM) to Underperform reducing its price target to $10 - $12 from $11 - $14 citing the potential cannabalizing effect of opening 10 - 15 new dialysis centers on its core business. For the first time, it will be directly competing with its customers (large dialysis service providers) for patients.
Analyst Gary Lieberman believes that this strategy is misguided because it will not synergize its home dialysis business and will potentially jeopardize its in-center revenue.
NXTM shares currently trade at $14.
Mutual fund ownership dropped from 207 to 192 from Q3 to Q4.